Rapid Micro Biosystems Q3 revenue $6.1M (+30% YoY); reaffirms FY23 guidance at least $22M

RAPID MICRO BIOSYSTEMS, INC.

2023-Q3 EPS reported -$0.96 revenue$16,182,000

Q3 revenue $6.1M, up 30% YoY; placed 5 Growth Direct systems, validated 4.
Net loss $13.4M ($0.31 EPS) vs $16.3M ($0.38) in Q3 2022; loss narrowed.
Recurring revenue $3.4M (+17%); cash $104M, no debt, runway into 2026.
Reaffirms FY23 revenue at least $22M (~30% growth) and at least 15 system placements.
Added a new top 5 global pharma customer; now serves two-thirds of top 20.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RAPID MICRO BIOSYSTEMS, INC. reported third quarter ended September 30, 2023 results: revenue $6.1 million, net income $13.4 million, EPS $0.31. Guidance reaffirmed.

Period: third quarter ended September 30, 2023
Revenue: $6.1 million
Net income: $13.4 million
EPS: $0.31
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue for the third quarter of 2023 increased 30% to $6.1 million

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

RAPID MICRO BIOSYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001380106-23-000173

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.